Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 9/20 | 0.40 |
| ▸ | JAK3 | P52333 | 6/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134961 | 0.94 | HRH4 (0.40) | EGLN2KDM1AMAOBHTR6CSNK2A1 | |
| SCHEMBL13688072 | 0.85 | CHEK2 (0.44) | CHEK2MAOBHTR6CSNK2A1 | |
| SCHEMBL10134996 | 0.85 | PRKCI (0.46) | CSNK2A1 | |
| SCHEMBL10134989 | 0.81 | HRH4 (0.55) | CSNK2A1 | |
| SCHEMBL10134981 | 0.80 | SMPD3 (0.47) | CSNK2A1 | |
| SCHEMBL10134963 | 0.80 | HRH3 (0.45) | CSNK2A1 | |
| SCHEMBL10134999 | 0.79 | HTR2C (0.48) | CSNK2A1 | |
| SCHEMBL13702845 | 0.78 | CSNK2A1 (0.40) | CHEK2MAOBHTR6CSNK2A1 | |
| SCHEMBL10134975 | 0.78 | PDE10A (0.41) | CSNK2A1 | |
| SCHEMBL10134945 | 0.77 | IRAK4 (0.43) | CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | EGLN2 2008/4885CHEK2 837/4885JAK2 84/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | EGLN2 2008/4885CHEK2 837/4885JAK2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.